Market Cap 496.14M
Revenue (ttm) 0.00
Net Income (ttm) -129.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 555,100
Avg Vol 364,472
Day's Range N/A - N/A
Shares Out 16.54M
Stochastic %K 27%
Beta 0.23
Analysts Strong Sell
Price Target $53.33

Company Profile

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its l...

Industry: Biotechnology
Sector: Healthcare
Phone: 650-489-9000
Address:
561 Eccles Avenue, South San Francisco, United States
bettyandrews92
bettyandrews92 Oct. 24 at 3:01 PM
$RAPT The read is IR to revenue conversion not just talk. After a two day run of 1x1s you typically see 20 to 30 outbound follow ups and 3 to 5 institutions start real diligence. That maps to EU orders rising from hundreds to low thousands of kits per month within 60 days
0 · Reply
victor32
victor32 Oct. 23 at 7:46 PM
$RAPT "Hopefully, following the close of today’s offering, we’ll begin to see some upward movement."
0 · Reply
Izaiah_Sparks_85
Izaiah_Sparks_85 Oct. 23 at 4:15 PM
0 · Reply
DonCorleone77
DonCorleone77 Oct. 22 at 12:50 PM
$RAPT Rapt Therapeutics 8.333M share Spot Secondary priced at $30.00
0 · Reply
TigerOfChicago
TigerOfChicago Oct. 22 at 11:54 AM
$PSTV $AIRE is about to rocket 🚀 $BYND $RAPT $AAPL
0 · Reply
TigerOfChicago
TigerOfChicago Oct. 22 at 11:23 AM
$RAPT I don’t think $BYND will stop it’s going towards 10 plus $PSTV $AIRE
0 · Reply
nUme22
nUme22 Oct. 21 at 8:42 PM
$RAPT public offering.. not good. will be back to 20 now.
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 21 at 8:27 PM
$RAPT https://www.sec.gov/Archives/edgar/data/1673772/000119312525245097/d44203d424b5.htm
0 · Reply
FilingTracker
FilingTracker Oct. 21 at 8:03 PM
$RAPT RAPT Therapeutics Announces Proposed Public Offering of Common Stock: https://www.globenewswire.com/news-release/2025/10/21/3170617/0/en/RAPT-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html
0 · Reply
anachartanalyst
anachartanalyst Oct. 21 at 2:02 PM
$RAPT https://anachart.com/wp-content/uploads/ana_temp/1761055319_soc-img.jpg
0 · Reply
Latest News on RAPT
RAPT Therapeutics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 2 months ago

RAPT Therapeutics Reports Second Quarter 2025 Financial Results


RAPT Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025, 8:00 AM EDT - 6 months ago

RAPT Therapeutics Reports First Quarter 2025 Financial Results


RAPT Therapeutics Announces $150 Million Private Placement

Dec 23, 2024, 7:10 AM EST - 10 months ago

RAPT Therapeutics Announces $150 Million Private Placement


RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24, 2024, 6:32 PM EDT - 1 year ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus


FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:41 AM EST - 1 year ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials


RAPT Therapeutics Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Third Quarter 2023 Financial Results


RAPT Therapeutics Reports Second Quarter 2023 Financial Results

Aug 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Second Quarter 2023 Financial Results


RAPT Therapeutics: Major Catalysts Are A Long Way Off

Jun 13, 2023, 3:59 PM EDT - 2 years ago

RAPT Therapeutics: Major Catalysts Are A Long Way Off


RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results


RAPT Therapeutics: Potential Strong Upside Ahead

Mar 30, 2023, 12:12 AM EDT - 2 years ago

RAPT Therapeutics: Potential Strong Upside Ahead


bettyandrews92
bettyandrews92 Oct. 24 at 3:01 PM
$RAPT The read is IR to revenue conversion not just talk. After a two day run of 1x1s you typically see 20 to 30 outbound follow ups and 3 to 5 institutions start real diligence. That maps to EU orders rising from hundreds to low thousands of kits per month within 60 days
0 · Reply
victor32
victor32 Oct. 23 at 7:46 PM
$RAPT "Hopefully, following the close of today’s offering, we’ll begin to see some upward movement."
0 · Reply
Izaiah_Sparks_85
Izaiah_Sparks_85 Oct. 23 at 4:15 PM
0 · Reply
DonCorleone77
DonCorleone77 Oct. 22 at 12:50 PM
$RAPT Rapt Therapeutics 8.333M share Spot Secondary priced at $30.00
0 · Reply
TigerOfChicago
TigerOfChicago Oct. 22 at 11:54 AM
$PSTV $AIRE is about to rocket 🚀 $BYND $RAPT $AAPL
0 · Reply
TigerOfChicago
TigerOfChicago Oct. 22 at 11:23 AM
$RAPT I don’t think $BYND will stop it’s going towards 10 plus $PSTV $AIRE
0 · Reply
nUme22
nUme22 Oct. 21 at 8:42 PM
$RAPT public offering.. not good. will be back to 20 now.
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 21 at 8:27 PM
$RAPT https://www.sec.gov/Archives/edgar/data/1673772/000119312525245097/d44203d424b5.htm
0 · Reply
FilingTracker
FilingTracker Oct. 21 at 8:03 PM
$RAPT RAPT Therapeutics Announces Proposed Public Offering of Common Stock: https://www.globenewswire.com/news-release/2025/10/21/3170617/0/en/RAPT-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html
0 · Reply
anachartanalyst
anachartanalyst Oct. 21 at 2:02 PM
$RAPT https://anachart.com/wp-content/uploads/ana_temp/1761055319_soc-img.jpg
0 · Reply
TigerOfChicago
TigerOfChicago Oct. 21 at 1:39 PM
$RAPT I like $BYND as well
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 1:08 PM
Wells Fargo has updated their rating for RAPT Therapeutics ( $RAPT ) to Overweight with a price target of 48.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:47 PM
Barclays updates rating for RAPT Therapeutics ( $RAPT ) to Overweight, target set at 35 → 58.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 11:35 AM
Clear Street has adjusted their stance on RAPT Therapeutics ( $RAPT ), setting the rating to Buy with a target price of 41 → 60.
0 · Reply
Quantumup
Quantumup Oct. 21 at 10:13 AM
JPMorgan y'day⬆️ $RAPT OW-$55 from N-$13/said Ph2 data for RPT904 in CSU is very compelling—believes data de-risks RAPT's broader pipeline—finds shrs attractive at current levels—ests peak sales of $2.X.5B & $400M in food allergy/CSU. $NVS Wells Fargo⬆️to $48/reit'd OW Barclays y'day⬆️to $58 from $35/reit'd OW Wells Fargo and Barclays said:
0 · Reply
KingsOnly
KingsOnly Oct. 21 at 10:02 AM
$RAPT RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
0 · Reply
BayAreaBiotech
BayAreaBiotech Oct. 21 at 3:15 AM
$RAPT we have come a long way in the last three weeks. After holding this for almost 18 months, it has started to pay off. Those who have held during the down time and have been patient are seeing the rewards. I regret selling half of my shares in late September but it’s impossible to predict the stock price.
0 · Reply
arthurkorff
arthurkorff Oct. 20 at 10:20 PM
$RAPT was there an offering?
0 · Reply
victor32
victor32 Oct. 20 at 10:08 PM
$RAPT over $40 tomorrow
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 9:59 PM
JP Morgan has adjusted their stance on RAPT Therapeutics ( $RAPT ), setting the rating to Overweight with a target price of 13 → 55.
0 · Reply
UgoGreg
UgoGreg Oct. 20 at 8:07 PM
$RAPT https://youtu.be/NjikYUHy2Zc
0 · Reply
Gbang77
Gbang77 Oct. 20 at 7:17 PM
$RAPT Rode this $32 to $37 this morning. Got out as soon as I could after being down 17%, with Webull glitching.
0 · Reply